.Attributes Medication, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- drug conjugate (ADC) tisotumab vedotin led to strengthened progression-free and general survival, causing FDA commendation and a brand new treatment possibility for patients.